• Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet

Nyheter fra ESMO

  • Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma Data support metronomic capecitabine as a potential adjuvant therapy for nasopharyngeal carcinoma 

    Created on: Jun 14, 2021 | 10:15 am
    Jun 14, 2021 | 10:15 am
  • Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab A novel checkpoint inhibitors combination of nivolumab plus relatlimab validate dual LAG-3 and PD-1 inhibition

    Created on: Jun 11, 2021 | 12:08 pm
    Jun 11, 2021 | 12:08 pm
  • EMA Recommends Extension of Indications for Daratumumab EMA Recommends Extension of Indications for Daratumumab New indications concern the treatment of patients with multiple myeloma and light chain amyloidosis

    Created on: Jun 10, 2021 | 14:23 pm
    Jun 10, 2021 | 14:23 pm
  • EMA Recommends Extension of Indications for Blinatumomab EMA Recommends Extension of Indications for Blinatumomab New indication concerns the treatment of paediatric patients with high-risk first relapsed Philadelphia chromosome negative CD19-positive B-precursor ALL

    Created on: Jun 9, 2021 | 09:10 am
    Jun 9, 2021 | 09:10 am
  • NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought Findings from the eNRGy1 global multicentre registry

    Created on: Jun 8, 2021 | 10:12 am
    Jun 8, 2021 | 10:12 am

Powered by Warp Theme Framework
  • Nyheter
  • Sykdommer
  • Kongresser
  • Samfunnet